Natera, Inc. , a global leader in cell-free DNA and genetic testing, today announced the enrollment of the first patients in the HEROES clinical trial. HEROES is a multi-center, phase II trial that ...

Prostate cancer affects one in eight men during their lifetime, making it the second most common cancer among American males.

Combining immunotherapy drugs with arthritis anti-inflammatory pills to blitz aggressive cancers has never been tried before ...

Given different scientific and clinical meeting schedules, considering advances in genitourinary oncology in novel therapies ...

In a groundbreaking clinical trial, immunotherapy alone eliminated rectal cancer in all 14 participants. This study, the ...

HEROES is Natera's first clinical trial using Signatera to guide de-escalation of therapy in patients with metastatic HER2+ breast cancer Approximately 170 patients are expected to enroll in up ...

Dr. Park shares the three biggest takeaways, in his opinion, to have come out of the ASCO GU Symposium, highlighting studies ...

One test could have prevented terminal prostate cancer, says patient - Research has shown that the use of the PSA test varies ...